Core Insights - UCB's drug, Zilucoplan (brand name: Zhuobeike), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult generalized myasthenia gravis (GMG) patients who are positive for acetylcholine receptor (AChR) antibodies [1] - Zilucoplan is the first and only subcutaneous self-administered C5 complement inhibitor, which can effectively block complement-mediated neuromuscular junction damage, allowing patients to self-administer the injection at home in just 5-8 seconds [1] - The prevalence of generalized myasthenia gravis in China is approximately 220,000 patients, with AChR antibodies detected in 80%-90% of cases [1] Drug Market Overview - Several drugs for generalized myasthenia gravis have entered the Chinese market recently, including UCB's other drug, Rozanolixizumab (brand name: Yudige), which was approved in March and covers both AChR-positive and MuSK-positive patients [1] - AstraZeneca's long-acting C5 complement inhibitor, Riluzole (brand name: WeiliRui), was approved in April for AChR-positive adult GMG patients [2] - Rongchang Biotech's Taitasip (brand name: Tai'ai) was also approved in May for AChR-positive adult GMG patients [2] - The number of subcutaneous injection options remains limited compared to intravenous formulations, with the approval of Efgartigimod (brand name: WeiliJia) in July last year, which requires a longer administration time of 30-90 seconds [2]

Core Insights - The long-acting C5 complement inhibitor, Riluzole injection (brand name: Weili Rui), has been approved for use in combination with conventional therapies for adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) [1][2] - The approval is based on positive results from the CHAMPION-MG Phase III study, which demonstrated that Riluzole significantly improved the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to placebo at the primary efficacy endpoint [1] - Long-term follow-up from an open-label extension study indicated that the clinical benefits of Riluzole persisted for up to 60 weeks, with a 71.1% reduction in the annual exacerbation rate per 100 patients compared to placebo [1] Industry Context - Generalized myasthenia gravis is a rare, debilitating chronic autoimmune neuromuscular disease affecting approximately 113,000 diagnosed patients in China [2] - The treatment of gMG requires early initiation and long-term maintenance, with Riluzole showing rapid and sustained improvement as reported by both patient self-assessments and physician evaluations [2] - Riluzole has already received approvals in the United States, European Union, Japan, and other regions for treating adult patients with anti-AChR antibody-positive gMG, and has multiple indications approved globally [2]